

\*518\*

**RNDr. Bořivoj Vojtěšek, DrSc.** (naroz. 1960)

Masarykův onkologický ústav

**molekulární a buněčná biologie**

návrh podává: Ústav živočišné fyziologie a genetiky AV ČR, v. v. i.

Ceskova p., Chichger H., Wallace M., Vojtěšek B., Hupp T.R. (2006) On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. *J Mol Biol.* 357(2), 442-456.

Tomasec P., Wang E.C., Davison A.J., Vojtěšek B., Armstrong M., Griffin C., McSharry B.P., Morris R.J., Llewellyn-Lacey S., Rickards C., Nomoto a., Sinzger C., Wilkinson G.W. (2005) Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. *Nat Immunol.* 6(2), 181-188.

Miller P., Ceskova P., Vojtesek B. (2005) Hsp90 is Essentials for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy. *J Biol Chem.* 280(8), 6682-6691.

Pospisilova S., Brazda V., Kucharikova K., Luciani M.G., Hupp T.R., Skladal P., Palecek E., Vojtesek B. (2004) Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. *Biochem J.* 378(Pt 3), 939-947.

Sherad M.A., Uldrijan S., Vojtesek B. (2003) Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells. *Cancer Res.* 63(21), 7176-7184.

Celkový SCI 4002, kumulativní IF 351,928.